TrademarkDir
DIVERGIMAB
LIVE

Serial Number

90826231

Owner

AbX Biologics, Inc.

Attorney

Mark Leonardo

First Use Date

Jul 13, 2021

Filing Date

Jul 13, 2021

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

DIVERGIMAB Trademark

Serial Number: 90826231 • Registration: 7323273

DIVERGIMAB is a trademark filed by AbX Biologics, Inc. on July 13, 2021. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

AbX Biologics, Inc. (2 trademarks)

480 Neponset Street, Suite 10B
Canton, MA 02021

Entity Type: 03

Trademark Details

Filing Date

July 13, 2021

Registration Date

March 5, 2024

First Use Anywhere

July 13, 2021

First Use in Commerce

July 13, 2021

Published for Opposition

July 19, 2022

Goods & Services

Scientific research services for others in the field of genetics and monoclonal antibodies; Research and development services in the field of monoclonal antibodies, namely, development of antibody-based therapeutics and discovery of reagents; Research and development services in the field of monoclonal antibodies, namely, generation of therapeutic and reagent antibodies; Genetic engineering services, namely, the production of genetically-engineered mice and monoclonal antibodies for others

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 5, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 5, 2024 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 30, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 30, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 30, 2024 REAP
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 30, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 29, 2024 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 15, 2023 CRFA
ASSIGNED TO LIE
Sep 15, 2023 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 1, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 22, 2023 GNRT
SU - NON-FINAL ACTION - WRITTEN
Mar 22, 2023 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Mar 8, 2023 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 3, 2023 AITU
USE AMENDMENT FILED
Feb 14, 2023 IUAF
TEAS STATEMENT OF USE RECEIVED
Feb 14, 2023 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 13, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 19, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 19, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 29, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 15, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 15, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 15, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 15, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jun 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jun 14, 2022 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 17, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 16, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 16, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 24, 2022 GNRN
NON-FINAL ACTION E-MAILED
Apr 24, 2022 GNRT
NON-FINAL ACTION WRITTEN
Apr 24, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 30, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 17, 2021 NWOS
NEW APPLICATION ENTERED
Jul 16, 2021 NWAP

Related Trademarks

More from this Owner

DIVERSIMAB

DIVERSIMAB

DIVERSIMAB

DIVERSIMAB

DIVERSIMAB

DIVERSIMAB